Pancreatic cancer: An emphasis on current perspectives in immunotherapy

Krishna Patel, Sohail Siraj, Chloe Smith, Maya Nair, Jamboor K. Vishwanatha, Riyaz Basha

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer affects both male and female individuals with higher incidences and death rates among the male population. Detection of this malignancy is delayed due to the lack of symptoms in the early-stage cancer, which makes it extremely difficult to treat. Identifying effective strategies has been a challenge for improving the survival rates in pancreatic cancer patients. Resistance to chemotherapy is often developed in pancreatic cancer treatment. Although many strategies are under clinical trials to target certain markers associated with cancer, immunotherapeutic approaches are currently gaining importance. Immunotherapy for pancreatic cancer is in the limelight after preclinical research showed some promise. Immunotherapy approaches were tested along with other treatment options to enhance the treatment effect. Adoptive cell transfer and immune checkpoint inhibitors are currently in clinical trials. The Food and Drug Administration approved pembrolizumab in a fast-tracked review for advanced pancreatic cancer patients. Pembrolizumab blocks the checkpoint protein, programmed cell death protein 1 (PD-1), on T cells to boost the response of the immune system against cancer cells, thereby shrinking tumors. The recent developments in immunotherapy and the early success in other cancers are encouraging to further test immunotherapy in pancreatic cancer. The combination of pembrolizumab and pelareorep, an isolate of human reovirus, is in phase II clinical study in metastatic disease. Depending on the results of current clinical trials and testing, the strategies in the pipeline are expected to increase the use of immunotherapy in the clinical testing setting. Success in immunotherapy is urgently needed to address the side-effects, treating patients with advanced disease and reducing metastasis for increasing the survival rate in pancreatic cancer patients.

Original languageEnglish
Pages (from-to)105-118
Number of pages14
JournalCritical Reviews in Oncogenesis
Volume24
Issue number2
DOIs
StatePublished - 1 Jan 2019

Fingerprint

Pancreatic Neoplasms
Immunotherapy
Neoplasms
Clinical Trials
Programmed Cell Death 1 Receptor
Survival Rate
Adoptive Transfer
United States Food and Drug Administration
Immune System
Therapeutics
Neoplasm Metastasis
T-Lymphocytes
Drug Therapy
Mortality
Incidence
Research
Population
pembrolizumab
Proteins

Keywords

  • Clinical trials
  • Immunotherapy
  • Pancreatic cancer
  • Programmed cell death protein 1

Cite this

@article{b30e41fcacf94f06a1f089ef86b7cd81,
title = "Pancreatic cancer: An emphasis on current perspectives in immunotherapy",
abstract = "Pancreatic cancer affects both male and female individuals with higher incidences and death rates among the male population. Detection of this malignancy is delayed due to the lack of symptoms in the early-stage cancer, which makes it extremely difficult to treat. Identifying effective strategies has been a challenge for improving the survival rates in pancreatic cancer patients. Resistance to chemotherapy is often developed in pancreatic cancer treatment. Although many strategies are under clinical trials to target certain markers associated with cancer, immunotherapeutic approaches are currently gaining importance. Immunotherapy for pancreatic cancer is in the limelight after preclinical research showed some promise. Immunotherapy approaches were tested along with other treatment options to enhance the treatment effect. Adoptive cell transfer and immune checkpoint inhibitors are currently in clinical trials. The Food and Drug Administration approved pembrolizumab in a fast-tracked review for advanced pancreatic cancer patients. Pembrolizumab blocks the checkpoint protein, programmed cell death protein 1 (PD-1), on T cells to boost the response of the immune system against cancer cells, thereby shrinking tumors. The recent developments in immunotherapy and the early success in other cancers are encouraging to further test immunotherapy in pancreatic cancer. The combination of pembrolizumab and pelareorep, an isolate of human reovirus, is in phase II clinical study in metastatic disease. Depending on the results of current clinical trials and testing, the strategies in the pipeline are expected to increase the use of immunotherapy in the clinical testing setting. Success in immunotherapy is urgently needed to address the side-effects, treating patients with advanced disease and reducing metastasis for increasing the survival rate in pancreatic cancer patients.",
keywords = "Clinical trials, Immunotherapy, Pancreatic cancer, Programmed cell death protein 1",
author = "Krishna Patel and Sohail Siraj and Chloe Smith and Maya Nair and Vishwanatha, {Jamboor K.} and Riyaz Basha",
year = "2019",
month = "1",
day = "1",
doi = "10.1615/CritRevOncog.2019031417",
language = "English",
volume = "24",
pages = "105--118",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
number = "2",

}

Pancreatic cancer : An emphasis on current perspectives in immunotherapy. / Patel, Krishna; Siraj, Sohail; Smith, Chloe; Nair, Maya; Vishwanatha, Jamboor K.; Basha, Riyaz.

In: Critical Reviews in Oncogenesis, Vol. 24, No. 2, 01.01.2019, p. 105-118.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pancreatic cancer

T2 - An emphasis on current perspectives in immunotherapy

AU - Patel, Krishna

AU - Siraj, Sohail

AU - Smith, Chloe

AU - Nair, Maya

AU - Vishwanatha, Jamboor K.

AU - Basha, Riyaz

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pancreatic cancer affects both male and female individuals with higher incidences and death rates among the male population. Detection of this malignancy is delayed due to the lack of symptoms in the early-stage cancer, which makes it extremely difficult to treat. Identifying effective strategies has been a challenge for improving the survival rates in pancreatic cancer patients. Resistance to chemotherapy is often developed in pancreatic cancer treatment. Although many strategies are under clinical trials to target certain markers associated with cancer, immunotherapeutic approaches are currently gaining importance. Immunotherapy for pancreatic cancer is in the limelight after preclinical research showed some promise. Immunotherapy approaches were tested along with other treatment options to enhance the treatment effect. Adoptive cell transfer and immune checkpoint inhibitors are currently in clinical trials. The Food and Drug Administration approved pembrolizumab in a fast-tracked review for advanced pancreatic cancer patients. Pembrolizumab blocks the checkpoint protein, programmed cell death protein 1 (PD-1), on T cells to boost the response of the immune system against cancer cells, thereby shrinking tumors. The recent developments in immunotherapy and the early success in other cancers are encouraging to further test immunotherapy in pancreatic cancer. The combination of pembrolizumab and pelareorep, an isolate of human reovirus, is in phase II clinical study in metastatic disease. Depending on the results of current clinical trials and testing, the strategies in the pipeline are expected to increase the use of immunotherapy in the clinical testing setting. Success in immunotherapy is urgently needed to address the side-effects, treating patients with advanced disease and reducing metastasis for increasing the survival rate in pancreatic cancer patients.

AB - Pancreatic cancer affects both male and female individuals with higher incidences and death rates among the male population. Detection of this malignancy is delayed due to the lack of symptoms in the early-stage cancer, which makes it extremely difficult to treat. Identifying effective strategies has been a challenge for improving the survival rates in pancreatic cancer patients. Resistance to chemotherapy is often developed in pancreatic cancer treatment. Although many strategies are under clinical trials to target certain markers associated with cancer, immunotherapeutic approaches are currently gaining importance. Immunotherapy for pancreatic cancer is in the limelight after preclinical research showed some promise. Immunotherapy approaches were tested along with other treatment options to enhance the treatment effect. Adoptive cell transfer and immune checkpoint inhibitors are currently in clinical trials. The Food and Drug Administration approved pembrolizumab in a fast-tracked review for advanced pancreatic cancer patients. Pembrolizumab blocks the checkpoint protein, programmed cell death protein 1 (PD-1), on T cells to boost the response of the immune system against cancer cells, thereby shrinking tumors. The recent developments in immunotherapy and the early success in other cancers are encouraging to further test immunotherapy in pancreatic cancer. The combination of pembrolizumab and pelareorep, an isolate of human reovirus, is in phase II clinical study in metastatic disease. Depending on the results of current clinical trials and testing, the strategies in the pipeline are expected to increase the use of immunotherapy in the clinical testing setting. Success in immunotherapy is urgently needed to address the side-effects, treating patients with advanced disease and reducing metastasis for increasing the survival rate in pancreatic cancer patients.

KW - Clinical trials

KW - Immunotherapy

KW - Pancreatic cancer

KW - Programmed cell death protein 1

UR - http://www.scopus.com/inward/record.url?scp=85073734598&partnerID=8YFLogxK

U2 - 10.1615/CritRevOncog.2019031417

DO - 10.1615/CritRevOncog.2019031417

M3 - Article

C2 - 31679206

AN - SCOPUS:85073734598

VL - 24

SP - 105

EP - 118

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 2

ER -